The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure.

The aim of this study is to find out if using a certain kind of mesh can reduce the chances of hiatal hernias coming back after anti-reflux surgery. The mesh used is approved by the U.S. Food and Drug Administration (FDA). 

Participants undergoing antireflux surgery will be assigned to one of two groups, a group that has surgery with mesh, or a group that has surgery without mesh. 

Any required post-surgical visits will be standard-of-care visits that participants would have regardless of study participation.  

This clinical trial is for men and women who have Multiple Myeloma that is either unresponsive to prior treatment or has relapsed.
   

This clinical trial is for men and women who have completed all the requirements for a corresponding parent treatment study of AAA617. 
   
In this study, participants will need to visit the study doctor about 2 times per year (every 6 to 8 months) which will include having routine blood and urine testing done at each visit.
   
Participation is expected to last up to 10 years from the first dose of AAA617 received on the parent treatment study.

This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory).

CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). CB-012 is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA).

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of participants with unresectable Hepatocellular Carcinoma (HCC, a.k.a. liver cancer).

Eye90 is comprised of tiny glass beads containing yttrium-90 (Y90), a radioactive material. The beads are delivered in and around the tumor(s) through a tiny catheter placed through the artery of the groin or wrist and into one or more branches of the artery of the liver under x-ray camera guidance.

This study is being done to determine if we can lower the chance of diffuse large B-cell lymphoma (DLBCL) growing or spreading by adding treatment to the usual therapy.

This clinical trial is for adult participants who have triple-negative breast cancer (TNBC).
   
The purpose of this study is to evaluate the safety and effectiveness of the study drug datopotamab deruxtecan (also called Dato-DXd) given in combination with another investigational drug called durvalumab.
   
Dato-DXd and Durvalumab are experimental, which means that they are being tested and are not approved by the United States Food and Drug Administration (FDA).
   

This clinical trial is for men and women with myelofibrosis.
   
The purpose of this study is to test the safety and tolerability of INCB057643 in combination with ruxolitinib on people with myelofibrosis. 
   

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).

Camizestrant is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA).